—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Insmed Inc (INSM) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for INSM, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.33 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How INSM has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.33 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Insmed Inc moved 0.33% on average · correlation 0.05 · higher than 32% of US names
  • Beta, last 3 months −0.40 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.09% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +2.71% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against INSM on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Insmed Inc

INSM in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Insmed develops and sells medicines for serious and rare diseases, with commercial operations across the United States, Europe and Japan. Its approved product, Arikayce, treats a rare lung infection, and it is advancing brensocatib through late-stage trials for bronchiectasis and related inflammatory conditions. The company also runs earlier-stage programmes in inhaled pulmonary hypertension treatment, gene therapy and antibody research across respiratory and rare disease areas. It is headquartered in Bridgewater, New Jersey.
Where it sits in the stack
Insmed carries no seat in Rubin, our AI infrastructure index, because it is a biotech and sits outside the compute and hardware build-out the index tracks. It belongs instead to the healthcare sleeve of our broader Nasdaq-100 universe, held for its rare-disease drug pipeline rather than any AI-related exposure.
Who it is priced against
Our peer group holds no comparison set for this name. The comparison the market often draws is with other rare-disease and respiratory biotechs, such as Vertex Pharmaceuticals.
Why Closelooknet tracks it
Insmed is a Nasdaq-100 constituent but has no Rubin or Halo seat, since it falls outside our AI infrastructure coverage. It does not yet carry a Closelooknet score, and the diary has not quoted it in past editions.
What the diary watches
The diary watches for trial results on brensocatib and the other late-stage programmes, since a readout there would reset how the pipeline's risk is read.

Insmed Inc (INSM) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Goldman Sachs, 2026-09-24

The Street on this name

Analyst actions and the latest print for INSM from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Goldman Sachs — target 188 Target set to $188 (+58.9% to spot) 2026-09-24
  • Price target Roth Capital — target 198 from 212 Target cut to $198 from $212 (+58% to spot) 2026-09-15

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Insmed Inc (INSM)?

Insmed Inc trades as INSM on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is INSM in a Closelooknet index?

Not currently — Insmed Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does INSM trade against its moving averages?

Downtrend stack: Trades -1.2% vs the 50-day and -12.8% vs the 200-day average, 44.6% below the 52-week high and +30.4% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Insmed Inc trade when bond yields rise?

Over the past year Insmed Inc had a beta of 0.33 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 32% of US names. On the 10 sessions in which long bonds fell most it moved −1.09% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Insmed Inc do?

Insmed develops and sells medicines for serious and rare diseases, with commercial operations across the United States, Europe and Japan. Its approved product, Arikayce, treats a rare lung infection, and it is advancing brensocatib through late-stage trials for bronchiectasis and related inflammatory conditions. The company also runs earlier-stage programmes in inhaled pulmonary hypertension treatment, gene therapy and antibody research across respiratory and rare disease areas. Our peer group holds no comparison set for this name. The comparison the market often draws is with other rare-disease and respiratory biotechs, such as Vertex Pharmaceuticals.

Where does Insmed Inc sit in the AI build-out?

Insmed carries no seat in Rubin, our AI infrastructure index, because it is a biotech and sits outside the compute and hardware build-out the index tracks. It belongs instead to the healthcare sleeve of our broader Nasdaq-100 universe, held for its rare-disease drug pipeline rather than any AI-related exposure. Insmed is a Nasdaq-100 constituent but has no Rubin or Halo seat, since it falls outside our AI infrastructure coverage. It does not yet carry a Closelooknet score, and the diary has not quoted it in past editions.

What has Wall Street done on Insmed Inc recently?

The most recent analyst action on Insmed Inc on the Closelooknet wire is a price target by Goldman Sachs on 2026-09-24 (target 188). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for INSM, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.